Welcome to our dedicated page for Ani Pharmaceutic SEC filings (Ticker: ANIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing FDA warnings, patent cliffs, or controlled-substance quotas in ANI Pharmaceuticals’ disclosures can feel like decoding another language. Each annual report blends clinical trial data, DEA quota details, and manufacturing risk factors that easily surpass 200 pages. If you have ever searched for “ANI Pharmaceuticals insider trading Form 4 transactions” or tried to locate one footnote on steroid revenue, you know the challenge.
Stock Titan turns those challenges into clarity. Our platform delivers AI-powered summaries the moment an ANI Pharmaceuticals quarterly earnings report 10-Q filing or 8-K hits EDGAR, highlighting revenue by therapeutic class, fresh FDA correspondence, and supply-chain updates. Need real-time alerts? We surface ANI Pharmaceuticals Form 4 insider transactions real-time so you can monitor executive buys and sells minutes after they post. From the ANI Pharmaceuticals annual report 10-K simplified to every ANI Pharmaceuticals 8-K material events explained, you receive concise language, key metrics, and cross-linked definitions—no accounting degree required.
Below you will find every filing type—10-K, 10-Q, 8-K, S-8, DEF 14A—each paired with an AI snapshot that answers the questions investors actually ask: cash flows by product line, R&D spend on rare-disease assets, or how “ANI Pharmaceuticals proxy statement executive compensation” aligns with pipeline milestones. Use our tools to:
- Run an “ANI Pharmaceuticals earnings report filing analysis” in seconds
- Track “ANI Pharmaceuticals executive stock transactions Form 4” before market open
- Master “understanding ANI Pharmaceuticals SEC documents with AI” without sifting through PDFs
Whether you are hunting for segment profitability or compliance triggers, Stock Titan delivers ANI Pharmaceuticals SEC filings explained simply—so you focus on decisions, not document digging.
Antonio R. Pera, a director of ANI Pharmaceuticals, Inc. (ANIP), reported the sale of 5,421 shares of the issuer's common stock on 08/20/2025 at a weighted average sales price of $89.73 per share, reducing his direct holdings to 29,952 shares. The Form 4 notes the shares were sold in multiple trades at prices ranging from $89.27 to $90.18. The filing was signed on behalf of Mr. Pera by an attorney-in-fact.
Form 144 notice for ANI Pharmaceuticals, Inc. (ANIP) reports a proposed sale of 5,421 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $486,406.81. The filing states the shares represent restricted stock acquired in two grants: 5,000 shares on 03/23/2022 and 421 shares on 08/05/2022, with corresponding payment dates matching acquisition dates. The sale is approximately dated 08/20/2025 and listed for execution on NASDAQ. The filer certifies they are not aware of undisclosed material adverse information about the issuer. No securities of the issuer were reported sold by the filer in the past three months.
ANI Pharmaceuticals (ANIP) Form 144 shows a proposed sale of 14,675 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of $1,304,170.19, and an approximate sale date of 08/18/2025. The issuer has 21,688,772 shares outstanding. The filing lists acquisition details for the securities being sold: 1,072 shares vested 12/20/2021, 3,554 shares vested 08/31/2022, and 10,049 shares vested 05/09/2023, all described as restricted stock vesting under a registered plan for services rendered. The filing also records a sale on 08/18/2025 by Jeanne A Thoma of 6,865 shares for gross proceeds of $616,223.68. The filer attests there is no undisclosed material adverse information.
ANI Pharmaceuticals director Matthew J. Leonard reported the sale of 6,937 shares of ANIP common stock on 08/18/2025. The shares were sold in multiple trades at prices ranging from $87.66 to $88.36, with a weighted-average sale price of $88.17. After the transactions Mr. Leonard beneficially owned 9,392 shares, reported as directly owned. The Form 4 was filed as a single reporting person filing and is signed by an attorney-in-fact on behalf of Mr. Leonard.
This filing documents a routine insider disposition of equity by a director and provides the exact sale quantity, price range, weighted-average price, and resulting beneficial ownership shown on the Form 4.
Insider sale reported: ANI Pharmaceuticals director Patrick D. Walsh disposed of 9,000 shares of ANIP common stock on 08/15/2025 at $89.05 per share, according to this Form 4. After the sale he beneficially owned 70,048 shares. The form was signed by an attorney-in-fact on 08/18/2025. No derivative transactions or additional explanations are disclosed.
ANI Pharmaceuticals insider sales by Shanmugam Muthusamy The filing shows that Shanmugam Muthusamy, a director and an officer (Head of R&D, COO-Novitium Ops), reported sales of ANI Pharmaceuticals (ANIP) common stock on 08/14/2025 and 08/15/2025. On 08/14/2025 he sold 47,010 shares at a weighted average price of $89.48, leaving 584,910 shares reported as beneficially owned through Esjay LLC. On 08/15/2025 he sold 52,990 shares at a weighted average price of $87.15, leaving 531,920 shares reported as beneficially owned through Esjay LLC. The filing also reports indirect ownership of 5,000 shares held by SS Pharma LLC. The statement is signed by attorney-in-fact Meredith W. Cook on 08/18/2025.
ANI Pharmaceuticals insider sale reported. Chad Gassert, SVP - Corporate Development & Strategy, reported a disposition of 20,000 shares of ANI Pharmaceuticals common stock on 08/15/2025 at a weighted-average price of $86.97 per share. Following the reported transactions, the reporting person beneficially owns 173,226 shares indirectly through Chali Properties LLC, over which he holds voting and dispositive power.
The filing clarifies the sale was executed in multiple trades at prices ranging from $86.54 to $88.05. The form is signed by an attorney-in-fact on behalf of Mr. Gassert and lists his role with the company as an officer.
ANI Pharmaceuticals, Inc. (ANIP) Form 144 reports a proposed sale of 6,865 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $616,223.68. The filing lists the approximate number of shares outstanding as 21,688,772 and an approximate sale date of 08/18/2025 on NASDAQ.
The shares were acquired on 05/23/2024 as restricted stock from the issuer, with payment recorded on the same date. The filer reports no sales of the issuer's securities in the past three months and includes the standard representation that they do not possess undisclosed material adverse information.
ANI Pharmaceuticals (ANIP) Form 144 notice discloses a proposed sale of 6,937 common shares held by an insider through Morgan Stanley Smith Barney LLC, with an aggregate market value of $611,644.31 based on the filing. The shares represent a small portion of the company's outstanding common stock (21,688,772 shares outstanding) and the proposed sale is slated to occur on 08/18/2025 on NASDAQ.
The filing also lists the acquisition history for the shares being offered: 2,527 restricted shares acquired on 08/21/2024 and 4,410 restricted shares acquired on 05/21/2025, both issued by the company. No securities were reported sold by the person in the prior three months on this form, and the filer certifies that they have no undisclosed material adverse information.
ANI Pharmaceuticals (ANIP) Form 144 notice reports a proposed sale of 29,580 common shares through Morgan Stanley Smith Barney on 08/18/2025, with an aggregate market value of $2,612,419.82 and total shares outstanding listed as 21,688,772. The filer acquired these shares on 11/19/2021 as convertible preferred shares from the issuer and paid in cash. The filing also discloses a recent sale of 91,000 shares on 08/15/2025 generating $7,866,267.50. The notice includes the standard representation that the seller is unaware of undisclosed material adverse information.
FAQ
What is the current stock price of Ani Pharmaceutic (ANIP)?
What is the market cap of Ani Pharmaceutic (ANIP)?
